Opinion|Videos|March 19, 2025
New Approvals in HER2-Positive BTC: Zanidatamab - Key Findings from HERIZON-BTC-01 Study
Panelists discuss how the HERIZON-BTC-302 study demonstrated zanidatamab's efficacy in HER2-positive biliary tract cancer (BTC) with key end points presented at ASCO GI, while sharing insights on optimal dosing strategies and early real-world experience with this newly approved agent in the second-line setting.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Zanidatamab was recently approved. What were some key end points from the HERIZON-BTC-302 study at ASCO GI and what are your impressions?
- What is your dosing strategy with zanidatamab? Dr Ellis, can you share some highlights from a poster looking at optimizing zanidatamab’s dosing?
- For those with experience using zanidatamab in the 2L, what has your experience been? What outcomes have you seen in patients so far?
Advertisement
Related to this article
Two optimized CD33-directed CAR T-cell therapies generated complete remissions with incomplete count recovery in heavily pretreated relapsed/refractory AML.
Lung cancer experts discuss the optimal management of CNS disease in EGFR-mutated non–small cell lung cancer.
Data for fixed-duration regimens in CLL suggest benefits over chemoimmunotherapy but still require improvements for high-risk patients.
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
Iza-bren was approved in China for recurrent or metastatic ESCC following progression on platinum-based chemotherapy and PD-1/PD-L1 inhibition.
A research team from Huntsman Cancer Institute at the University of Utah showed a pathway-targeted therapy that could be an effective melanoma treatment.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Orelabrutinib produced efficacy improvements vs chemoimmunotherapy in previously untreated chronic lymphocytic leukemia.
Advertisement
Advertisement
Trending on OncLive
1
Subcutaneous Pembrolizumab Faces Scrutiny Over Convenience and Cost for Patients With Cancer
2
China’s NMPA Approves Iza-Bren for Pretreated Recurrent/Metastatic ESCC
3
Improved Outcomes for High-Risk CLL Remain Key Focus for Continued Development of Fixed-Duration Regimens
4
Cutting-Edge Drug Shows Promise for Patients With NRAS-Driven Melanoma
5